Our CEO Bill Enright recently spoke with Tyler Menichiello from Bioprocess Online about our proprietary ChAdOx and MVA viral vector platforms. Bill explains why our combination dosing approach has the potential to change outcomes for people with serious #infectiousdiseases: https://lnkd.in/epVD--eX #hepatitis #immunotherapy #innovation #biopharma
Barinthus Biotherapeutics
Biotechnology Research
Harwell, Oxfordshire 9,192 followers
Barinthus is a clinical-stage biopharmaceutical company developing novel T-cell immunotherapeutic candidates.
About us
Barinthus Biotherapeutics is a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. Helping people living with serious diseases and their families is the guiding principle at the heart of Barinthus Biotherapeutics. With a broad pipeline, built around four proprietary platform technologies: ChAdOx, MVA, SNAP-TI, and SNAP-CI; Barinthus Biotherapeutics is advancing a pipeline of five product candidates across a diverse range of therapeutic areas, including: VTP-300, an immunotherapeutic candidate designed as a potential component of a functional cure for chronic HBV infection; VTP-1000, an autoimmune candidate designed to utilize the SNAP-TI platform to treat patients with celiac disease; and VTP-850, a second-generation immunotherapeutic candidate designed to treat recurrent prostate cancer. Barinthus Biotherapeutics’ proven scientific expertise, diverse portfolio and focus on pipeline development uniquely positions the company to navigate towards delivering treatments for people with infectious diseases, autoimmunity and cancers that have a significant impact on their everyday lives.
- Website
-
https://www.barinthusbio.com
External link for Barinthus Biotherapeutics
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- Harwell, Oxfordshire
- Type
- Public Company
- Founded
- 2016
- Specialties
- Research, Immunotherapy, Infectious Disease, Oncology, Viral vectors, HBV, HPV, Prostate cancer, Non-small cell lung cancer, Hepatitis B, Celiac, SNAP, and nanoparticles
Locations
-
Primary
Units 6-10 Zeus Building, Rutherford Avenue
Harwell, Oxfordshire OX11 0DF, GB
-
20400 Century Blvd
Suite 210
Germantown, Maryland 20874, US
Employees at Barinthus Biotherapeutics
-
Nick Fullenkamp
Vice President of Corporate Development at Barinthus Biotherapeutics
-
Rohan Kulkarni, M.Sc., PhD.
Global Head of Toxicology and Pharmacology
-
Katie Anderson
Senior Director, Immunology
-
Dominick J. Laddy, Ph.D., P.M.P.
Project Director at International AIDS Vaccine Initiative (IAVI)
Updates
-
Our Chief Business Officer Graham Griffiths is on the move, meeting with people from all over the globe! Recently he traveled to China and spoke with potential investors and partners about Barinthus Bio’s innovative platform and portfolio of potential treatments for serious diseases. Learn how Barinthus Bio is advancing the next generation of antigen-specific immunotherapies for treating chronic infectious diseases, #autoimmunity and #cancer: https://lnkd.in/ewaij6jM #innovation #partnering #hepatitis #biopharma
Last week I joined a delegation of companies that visited Shanghai, Nanjing and Wuxi to explore opportunities for #biotech partnership and investment. Huge thanks 🤜 to the wonderful and impressive team at #HSBC and our many hosts in China for a fascinating, fun and productive trip with an amazing group of people representing great companies - including the opportunity to introduce spread the word about Barinthus Bio and its portfolio of medicines designed to treat #autoimmunity #cancer and #infectiousdiseases by inducing antigen-specific T cells. Simon Bumfrey Cora McLaren Joe Li Sherard Cowper-Coles China-Britain Business Council
-
-
At Barinthus Biotherapeutics we are celebrating #PRIDE month and supporting our #LGBTQIA+ community because diversity isn’t just beneficial—it’s essential for driving innovation and success. We strive to create an environment where every individual feels valued, respected, and empowered to bring their authentic self to work. #biotech #unity
-
-
#RECAP: Another whirlwind year at EASL | The Home of Hepatology annual conference in Milan, Italy. Our team, along with our partners at Arbutus Biopharma Corporation, were honored to share our research and #clinicaltrial findings as we work towards positively changing outcomes for people with #HepatitisB. Learn more about our poster and oral presentations at #EASL2024 here: https://lnkd.in/eXXAYkAz
-
-
At Barinthus, we’re focused on improving patient outcomes. As our Chief Business Officer Graham Griffiths puts it, meetings like #EASL2024 bring together a community of people who are passionate about working towards curing serious diseases. Read more about our work at this year’s EASL | The Home of Hepatology Congress: https://lnkd.in/eXXAYkAz #HepatitisB #innovation #biopharma #EASLcongress
-
“We believe these data are further evidence that VTP-300 could be a critical component of a functional cure regimen.” For #HCPs: Today our CEO Bill Enright explains how the new interim data, presented at the EASL | The Home of Hepatology 2024 Congress, shows our progress towards reshaping the #HepatitisB treatment landscape. Read more: https://lnkd.in/eXXAYkAz #EASL2024 #innovation #hepatitis #HBV #TheLiverMeeting2024 #EASLMeeting
-
-
Our VP of Corporate Development, Nick Fullenkamp, and Chief Scientific Officer, Nadege Pelletier, are at Biotechnology Innovation Organization #BIO2024. Schedule a meeting with us in San Diego to learn more about #partnering opportunities: https://lnkd.in/eEDtKaAK #immunotherapy #innovation #celiac #HBV #investors
-
-
Barinthus Biotherapeutics reposted this
We are highly encouraged by our data showing the promise of our HBV immunotherapy (VTP300) for increasing rates of functional cure. Stay tuned for the latest updates at #EASL 2024.
Our Chief Scientific Officer, Dr. Nadege Pelletier, has been featured in Health and Pharma during #HepatitisAwarenessMonth. Nadege details our #innovation and progress as we work towards advancing a potential functional cure for #hepatitisB: https://lnkd.in/ds5xsiEk #HepB #immunotherapy #biotechnews
-
Our Chief Scientific Officer, Dr. Nadege Pelletier, has been featured in Health and Pharma during #HepatitisAwarenessMonth. Nadege details our #innovation and progress as we work towards advancing a potential functional cure for #hepatitisB: https://lnkd.in/ds5xsiEk #HepB #immunotherapy #biotechnews
Advancing Hepatitis B Cure: A Closer Look at Barinthus Bio's VTP-300 Project with Dr. Nadege Pelletier
healthandpharma.net
-
On #WorldMenstrualHygieneDay, Barinthus associate project manager Lizzy Welsh speaks about the importance of raising awareness and ending the stigma surrounding menstruation and hormonal changes in the workplace. #MHDay2024